Skip to main content

FDA approves Flexion Therapeutics' pain treatment

The Food and Drug Administration approved Flexion Therapeutics Inc.'s (Nasdaq: FLXN) non-opioid steroid injection to treat knee pain. Shares of the pharmaceutical soared $2.81 to close at $29.93.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.